Literature DB >> 21760510

Hyper-IgD syndrome or mevalonate kinase deficiency.

Monique Stoffels1, Anna Simon.   

Abstract

PURPOSE OF REVIEW: The hyper-IgD and periodic fever syndrome (HIDS) is one of the classical monogenetic hereditary autoinflammatory disorders, and together with the more severe mevalonic aciduria it is also known as 'mevalonate kinase deficiency' (MKD). In this study, we will give an overview of the primary research on mevalonate kinase deficiency published in the past 2 years. RECENT
FINDINGS: Besides an inventory of a number of recent case reports, literature review shows there are several interesting developments in the basic field of research. First, a group of articles was recently published on chemically instead of genetically induced MKD mouse and cell models, investigating the effects of several isoprenoid pathway intermediates. Second, another study confirms a role for small GTPases and their isoprenylation in the inflammatory response in mevalonate kinase deficiency. Lastly, there are now, finally, modest new indications about the role of IgD.
SUMMARY: Both pathophysiological studies and clinical observations in the last 2 years have supported the central role of IL-1 in HIDS. There are some intriguing results and hypotheses about the link between isoprenoid metabolism and the IL-1 pathway through geranylgeranylation that deserve to be further examined.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21760510     DOI: 10.1097/BOR.0b013e328349c3b1

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  16 in total

1.  Mevalonate kinase deficiency nomenclature.

Authors:  Monique Stoffels; Jos W M van der Meer; Anna Simon
Journal:  Rheumatol Int       Date:  2013-08-07       Impact factor: 2.631

2.  Intermittent neutropenia as an early feature of mild mevalonate kinase deficiency.

Authors:  Nima Parvaneh; Vahid Ziaee; Mohammad-Hassan Moradinejad; Isabelle Touitou
Journal:  J Clin Immunol       Date:  2013-11-01       Impact factor: 8.317

3.  Mevalonate kinase genotype in children with recurrent fevers and high serum IgD level.

Authors:  Achille Stabile; Adele Compagnone; Salvatore Napodano; Carmela Gerarda Luana Raffaele; Maria Patti; Donato Rigante
Journal:  Rheumatol Int       Date:  2012-12-13       Impact factor: 2.631

Review 4.  Regulation of dolichol-linked glycosylation.

Authors:  Michael Welti
Journal:  Glycoconj J       Date:  2012-06-21       Impact factor: 2.916

Review 5.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 6.  Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Rheumatology (Oxford)       Date:  2015-07-23       Impact factor: 7.580

Review 7.  Inborn errors of metabolism underlying primary immunodeficiencies.

Authors:  Nima Parvaneh; Pierre Quartier; Parastoo Rostami; Jean-Laurent Casanova; Pascale de Lonlay
Journal:  J Clin Immunol       Date:  2014-08-01       Impact factor: 8.317

Review 8.  A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin.

Authors:  Seza Ozen; Yelda Bilginer
Journal:  Nat Rev Rheumatol       Date:  2013-11-19       Impact factor: 20.543

Review 9.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 10.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.

Authors:  Charles A Dinarello; Anna Simon; Jos W M van der Meer
Journal:  Nat Rev Drug Discov       Date:  2012-08       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.